Unique ID issued by UMIN | UMIN000020456 |
---|---|
Receipt number | R000023636 |
Scientific Title | A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatment |
Date of disclosure of the study information | 2016/01/07 |
Last modified on | 2018/08/08 17:44:24 |
A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatment
A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatment
A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatment
A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatment
Japan |
Peripheral neuropathy
Gastrointestinal surgery |
Malignancy
NO
To study whether consumption of cystine and theanine ameliorate peripheral neuropathy caused by oxaliplatin in colon cancer patients receiving mFOLFOX6 therapy which is a combination of oxaliplatin, fluorouracil and folinic acid by comparing with no sonsumpting control.
Efficacy
Exploratory
Pragmatic
Phase II
Suppressive effect of cystine and theanine on occurrence of peripheral neuropathy during receiving mFOLFOX6 therapy (Max. 6 months)
State of occurrence of other adverse events of grade 2 or more.
Total amount of administered oxaliplatin
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Prevention
Food |
Ingestion of supplement containing 700mg of cystine and 280mg of theanine once a day during receiving mFOLFOX6 therapy (Max. 6 months)
No ingestion of supplement instead of cystine and theanine during receiving mFOLFOX6 therapy.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1.From 20 to 80 years old.
2.Performance status 0-1.
3.Able to oral ingestion.
4.Received a written informed consent by patient's self-determination.
1.Active infection.
2.Poorly controlled hypertension.
3.Poorly controlled diabetes.
4.Clinically important cardiac disease.
5.Severe pulmonary disease (e.g. interstitial pneumonia , fibrosis, severe emphysema).
6.HIstory of clinically important psychopathic disorder or central nervous system damage.
7.Continuous systemic administration (iv or po) of steroid.
8.Pregnancy, breast-feeding, possible pregnancy and willing to be pregnant.
9.Participation for other studies.
10.Impossible of oral ingestion.
11.Judged ineligible by the principal investigator or sub-investigators.
40
1st name | |
Middle name | |
Last name | Takashi Tsuchiya |
Sendai City Medical Center, Sendai Open Hospital
Director of the hospital, digestive surgery
5-22-1 Tsurugaya , Miyagino-ku, Sendai City, Miyagi
022-252-1111
tsuchiya@openhp.or.jp
1st name | |
Middle name | |
Last name | Takashi Tsuchiya |
Sendai City Medical Center, Sendai Open Hospital
Director of the hospital, digestive surgery
5-22-1 Tsurugaya , Miyagino-ku, Sendai City, Miyagi
022-252-1111
tsuchiya@openhp.or.jp
Sendai City Medical Center, Sendai Open Hospital
Ajinomoto Co., Inc.
Profit organization
Japan
Shirakawa Kosei General Hospital
NO
仙台市医療センター仙台オープン病院(宮城県)
白河厚生病院(福島県)
2016 | Year | 01 | Month | 07 | Day |
Unpublished
Completed
2014 | Year | 11 | Month | 21 | Day |
2015 | Year | 01 | Month | 28 | Day |
2018 | Year | 08 | Month | 15 | Day |
2018 | Year | 08 | Month | 31 | Day |
2018 | Year | 09 | Month | 30 | Day |
2018 | Year | 10 | Month | 31 | Day |
2016 | Year | 01 | Month | 06 | Day |
2018 | Year | 08 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023636